Novo Holdings and TA Associates have entered into an agreement for Novo Holdings to invest in Biocomposites, a UK-based medical devices company specializing in infection management for bone and soft tissue. TA Associates, the majority shareholder since 2017, will reinvest alongside Novo Holdings and Biocomposites’ management, resulting in shared control of the company.

Biocomposites, headquartered in Keele, UK, is known for its innovative calcium compounds and specialty polymer products, including STIMULAN. This product is the only calcium matrix carrier platform approved for delivering antibiotics to infected and non-infected sites in bone and soft tissue. Trusted by surgeons in over 100 countries, Biocomposites has over 30 years of experience and is involved in more than one million procedures annually across various medical specialties.

Since partnering with TA in 2017, Biocomposites has seen substantial growth, tripling its revenues and expanding geographically while diversifying its product offerings. The company has also completed two strategic acquisitions, enhancing its international presence and entering new therapeutic areas. With the new investment from Novo Holdings and continued support from TA, Biocomposites aims to build on this success by expanding its global reach and advancing its innovative product pipeline.

Henrik Kjær Hansen, a senior partner at Novo Holdings, expressed enthusiasm about the partnership, highlighting Biocomposites’ alignment with their life sciences investment portfolio. He emphasized the company’s growth potential and the commitment to support its international expansion and innovation in infection management solutions.

Michael Harris, CEO of Biocomposites, noted that the investment validates the company’s achievements and future growth prospects. He believes that with the combined expertise of Novo Holdings and TA Associates, Biocomposites is well-positioned to enhance its offerings in infection management and improve patient outcomes globally.

Birker Bahnsen, Managing Director at TA, praised Biocomposites for its pioneering role in infection management and its ability to scale internationally while diversifying its product portfolio. He expressed excitement about collaborating with Novo Holdings and the management team for the next phase of growth.

The financial terms of the transaction were not disclosed. Jefferies International Limited acted as the exclusive financial advisor to TA and Biocomposites, while Goodwin Procter LLP served as legal counsel for them. Novo Holdings was advised by Kirkland & Ellis International LLP and Linklaters LLP, and Alvarez & Marsal provided financial and tax vendor due diligence for Biocomposites, with additional advisory support from Squire Patton Boggs (UK) LLP, KPMG LLP (UK), and Jamieson Corporate Finance.